全文获取类型
收费全文 | 34388篇 |
免费 | 3016篇 |
国内免费 | 1826篇 |
专业分类
耳鼻咽喉 | 37篇 |
儿科学 | 668篇 |
妇产科学 | 172篇 |
基础医学 | 5092篇 |
口腔科学 | 124篇 |
临床医学 | 2968篇 |
内科学 | 14194篇 |
皮肤病学 | 228篇 |
神经病学 | 320篇 |
特种医学 | 585篇 |
外国民族医学 | 4篇 |
外科学 | 1484篇 |
综合类 | 6042篇 |
现状与发展 | 11篇 |
一般理论 | 1篇 |
预防医学 | 2504篇 |
眼科学 | 99篇 |
药学 | 2481篇 |
10篇 | |
中国医学 | 1461篇 |
肿瘤学 | 745篇 |
出版年
2024年 | 48篇 |
2023年 | 442篇 |
2022年 | 962篇 |
2021年 | 1260篇 |
2020年 | 1171篇 |
2019年 | 1179篇 |
2018年 | 1047篇 |
2017年 | 1174篇 |
2016年 | 1334篇 |
2015年 | 1385篇 |
2014年 | 2105篇 |
2013年 | 2307篇 |
2012年 | 2007篇 |
2011年 | 2330篇 |
2010年 | 1750篇 |
2009年 | 1617篇 |
2008年 | 1610篇 |
2007年 | 1754篇 |
2006年 | 1705篇 |
2005年 | 1414篇 |
2004年 | 1243篇 |
2003年 | 1109篇 |
2002年 | 998篇 |
2001年 | 990篇 |
2000年 | 835篇 |
1999年 | 661篇 |
1998年 | 595篇 |
1997年 | 574篇 |
1996年 | 493篇 |
1995年 | 468篇 |
1994年 | 405篇 |
1993年 | 341篇 |
1992年 | 300篇 |
1991年 | 222篇 |
1990年 | 193篇 |
1989年 | 167篇 |
1988年 | 175篇 |
1987年 | 142篇 |
1986年 | 110篇 |
1985年 | 127篇 |
1984年 | 95篇 |
1983年 | 70篇 |
1982年 | 65篇 |
1981年 | 56篇 |
1980年 | 60篇 |
1979年 | 34篇 |
1978年 | 43篇 |
1977年 | 22篇 |
1976年 | 11篇 |
1973年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
目的:建立鼠巨细胞病毒(MCMV)感染C57BL/6小鼠急性肝炎模型并对其感染特点进行分析及鉴定。方法:将24 只C57BL/6小鼠随机分为阴性对照组(n =12)及病毒感染组(n =12),病毒感染组腹腔注射1.0×106 PFU(200 μL)MCMV悬液,阴性对照组注射等体积小鼠胚胎成纤维细胞(MEF)悬液。于感染后第3天和第7天取外周血分离血清检测谷丙转氨酶(ALT)及谷草转氨酶(AST)。同时进行肝组织病毒分离、组织病理学及MCMV IE和M55基因、细胞因子白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)、肿瘤坏死因子α(TNF-α)的检测。结果:病毒感染组肝组织匀浆病毒分离均为阳性,肝炎发生率为100%。在感染后第3天即发生肝炎病理改变,病毒感染组血清ALT及AST较阴性对照组明显升高(P <0.01);病毒感染组肝脏HE染色第3天可见局灶性炎性细胞浸润及肝脏点灶状坏死,持续至第7天,Ishak评分较阴性对照组明显升高(P <0.01);在感染后第3天病毒感染组肝组织内可检测到MCMV IE及M55基因,且在感染后第7天仍可测得IE基因;感染后第3天及第7天病毒感染组炎性细胞因子IL-6、TNF-α及IL-1β mRNA表达水平明显升高(P <0.05)。 结论:成功建立MCMV感染C57BL/6小鼠急性动物肝炎模型,其感染表现主要集中在急性感染前期。 相似文献
13.
Although hepatitis E virus (HEV) is the primary cause of enterically transmitted acute hepatitis and jaundice in developing countries, locally acquired HEV infections are increasing in nonendemic countries. As such, HEV is emerging as an underdiagnosed cause of infection. This report describes three clinically variable cases of HEV infection with unusual clinical presentations. These cases highlight the fact that HEV should be considered in the differential diagnosis of patients with unexplained hepatitis (acute or chronic) with or without extrahepatic manifestations. HEV should also be considered in patients with persistently elevated liver enzymes who have not travelled to known HEV-endemic regions. Lack of knowledge among physicians and an absence of standardized diagnostic tests may result in increased morbidity and mortality from HEV infection. 相似文献
14.
Hepatitis C is a major public health problem worldwide. This disease is caused by the hepatitis C virus, which is characterised by its genetic diversity. The infection is usually asymptomatic. However, between 60% and 80% of HCV-infected individuals will progress to chronic hepatitis, 20% to liver cirrhosis in the medium-to long-term and, each year, between 1% and 4% of these patients with cirrhosis will develop hepatocellular carcinoma (HCC). A Spanish consensus document has recently been drafted to diagnose hepatitis C in a single step, consisting of active investigation (antibodies and viremia) in a single sample, which according to the experts, would reduce the time to access treatment and avoid tracking losses. To definitively change the hepatitis C treatment paradigm, direct-acting antiviral drugs (DAAs) have been approved, whose development has been based on achieving cure rates close to 100% regardless of the genotype of the virus, ie, pangenotypes, with good tolerance and bioavailability. These drugs have constituted a real therapeutic revolution. Supplement information: This article is part of a supplement entitled «SEIMC External Quality Control Programme. Year 2016», which is sponsored by Roche, Vircell Microbiologists, Abbott Molecular and Francisco Soria Melguizo, S.A.© 2019 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosasy Microbiología Clínica. All rights reserved. 相似文献
15.
16.
目的:分析延续护理干预对慢性乙型肝炎患者抗病毒治疗依从性的影响。方法:研究选取2017年1月~2017年12月某院肝二病区收治的112例乙型肝炎患者和2018年1月~2018年12月收治的98例乙型肝炎病毒患者作为研究对象,所有患者均进行抗病毒治疗,回顾性分析患者的病历资料。将2017年收治的112例患者作为常规组实施常规护理,将2018年收治的98例患者的作为研究组实施延续性护理,比较两组的护理效果。结果:研究组的治疗依从率为93.88%(92例),远高于常规组的77.68%(87例),两组数据比较存在统计学意义(P<0.05)。结论:延续性护理措施可以有效提高慢性乙型肝炎抗病毒治疗的依从性,可以在临床中推广使用。 相似文献
17.
Auda A. Eltahla Fabio Luciani Peter A. White Andrew R. Lloyd Rowena A. Bull 《Viruses》2015,7(10):5206-5224
The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes, as well as the large genetic diversity between HCV strains. On the other hand, the use of interferon-α-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase (RdRp) has been targeted for antiviral development. Direct acting antivirals (DAA) have been identified which bind to one of at least six RdRp inhibitor-binding sites, and are now becoming a mainstay of highly effective and well tolerated antiviral treatment for HCV infection. Here we review the different classes of RdRp inhibitors and their mode of action against HCV. Furthermore, the mechanism of antiviral resistance to each class is described, including naturally occurring resistance-associated variants (RAVs) in different viral strains and genotypes. Finally, we review the impact of these RAVs on treatment outcomes with the newly developed regimens. 相似文献
18.
19.
20.
Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C 下载免费PDF全文
Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Akira Kawano Kazuhiro Takahashi Kazufumi Dohmen Takeaki Satoh Koichi Azuma Makoto Nakamuta Toshimasa Koyanagi Kazuhiro Kotoh Shinji Shimoda Jun Hayashi The Kyushu University Liver Disease Study Group 《Journal of gastroenterology and hepatology》2015,30(8):1309-1316